Sugar.IQ with Watson Cognitive App to Preview at Health 2.0 Conference
DUBLIN and SANTA CLARA, Calif. - Sept. 27, 2016 - Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that Sugar.IQ with Watson, the first-of-its-kind cognitive app that helps detect important patterns and trends for people with diabetes, is now in live use for the first time. With app development now completed, the first users are participating in real-world testing of the final release candidate. Developed with IBM Watson Health, the Sugar.IQ app will be demonstrated at the 10 th Annual Health 2.0 Fall Conference in Santa Clara, Calif.
The Sugar.IQ appuses real-time continuous glucose monitoring (CGM) and insulin information from Medtronic pumps and glucose sensors. It leverages IBM cognitive computing power, combined with Medtronic's expertise in diabetes, to find hidden patterns in diabetes data and will offer real-time and personalized insights so that people with diabetes can spend less time worrying about their data and have more freedom to simply enjoy life. The appwill provide individualized guidance in understanding and helping to manage elements of daily diabetes decisions by creating a single platform that brings together relevant data and provides context and insights.
"We have made great progress in development of the Sugar.IQ appsince unveiling the first research concepts at CES 2016," said Annette Brüls, president, Diabetes Service and Solutions at Medtronic. "Through our collaboration with IBM Watson Health, Medtronic will arm people with diabetes with a unique solution that could uncover previously unknown patterns while serving as a personal assistant that offers meaningful information when it matters to helptransform diabetes care for greater freedom and better health."
In the coming days, Medtronic and IBM will offer a limited launch of the application to 100 MiniMed® Connect mobile accessory users, who will have the opportunity to explore the design and usability of the Sugar.IQ app, and provide valuable feedback on their experience ahead of the apps broader roll-out later this year.
"The Medtronic-IBM partnershiphas advanced rapidly and today's debut of the final release candidate of the Medtronic Sugar.IQ appwith Watson is proof positive of that progress," said Deborah DiSanzo, general manager for IBM Watson Health. "We look forward to learning from the pilot how Watson-derived insights can potentially helppeople living with diabetes better manage their condition."
The final release candidate of the Sugar.IQ appwill also be demonstrated on Health 2.0's Main Stage during a live on-stage panel presentation titled "Data Drives Decisions & Discovery: Intelligence for a New Era" on Sept. 27, 2016 at 10:45 a.m.
The Sugar.IQ appwill helpanswer key questions that people with diabetes have about their current health status, about where their health is trending and what actions they can take to better manage their diabetes in the future as part of their disease-management plan with their provider.
Once commercially available, the Sugar.IQ appwill be offered to people with diabetes who use Medtronic's continuous glucose monitoring sensors and insulin pumps and will be a companion appfor those using the MiniMed Connect mobile accessory.
About the Diabetes Groupat Medtronic
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.
Medtronic plc ( www.medtronic.com ), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 88,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.
Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
Last updated on: 28/09/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.